Asunaprevir
Asunaprevir is an experimental drug candidate for the treatment of hepatitis C. It is undergoing development by Bristol-Myers Squibb and is currently in Phase III clinical trials.
Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3.
Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.
